MAP2K7 and non-small cell lung carcinoma: Lastly, our results are compatible with recent studies, which report in patients with NSCLC the encouraging therapeutic results shown by treatment strategies involving the combination of MEK inhibitors with other therapies such as BRAF inhibition, immunotherapy or chemotherapy [118].